Showing articles associated with Christina Dold
Dr Christina Dold has been part of the Oxford Vaccine Group since 2011. She is a senior postdoctoral scientist, specialising in preclinical and Phase I vaccine development.
What is your main area of interest/expertise?
I am the lab lead for preclinical development of vaccines against a variety of diseases at the Oxford Vaccine Group including MenB, Q-fever and plague.
What are you working on right now?
I am collaborating with researchers at the John Radcliffe hospital and throughout the university to provide samples for various immunological studies on SARS-CoV-2 natural infection. I am coordinating the containment level 3 laboratory aspects of the vaccine trial and a drug trial, CATALYST as well as studies focusing on immune responses in patients in the hospital and community with confirmed COVID-19. Currently, I am focussing on assessing B cell and antibody responses induced by natural infection and the University's COVID-19 vaccine.
Why is Oxford a good place to work in this field of research?
The combination of Oxford’s multidisciplinary expertise and extensive infrastructure ensured that we could implement research activities and vaccine development immediately, following the outbreak.
Find out more about Christina
